Epidemiology and Immunology of Hemophilia A Inhibitors
NCT00005518 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-05-13
Summary
To determine the risk factors associated with inhibitor formation in hemophilia A and to study the mechanism of tolerance in the murine hemophilia A model.
Conditions
- Blood Disease
- Hemophilia A
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Principal Investigators
-
M.V. Ragni · University of Pittsburgh
Eligibility
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-06-30
- Completion
- 2003-08-31
More Related Trials
-
A Feasibility Study to Collect Data in Patients With Haemophilia
NCT00798499 ·Status: COMPLETED
-
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
NCT02225483 ·Status: COMPLETED
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Genetic Susceptibility to Factor VIII Inhibitors
NCT00344435 ·Status: COMPLETED
-
Rituximab to Treat Severe Hemophilia A
NCT00331006 ·Status: COMPLETED ·Phase: PHASE2
-
Emicizumab in Acquired Hemophilia A
NCT04188639 ·Status: COMPLETED ·Phase: PHASE2
-
Preventing Inhibitor Recurrence Indefinitely
NCT04621916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
NCT06155955 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Understanding Hemophilia A and B Drug Dosage Administration Patterns
NCT03248141 ·Status: TERMINATED
-
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
NCT01561391 ·Status: COMPLETED ·Phase: PHASE4
-
PF-06741086 Multiple Dose Study in Severe Hemophilia
NCT02974855 ·Status: COMPLETED ·Phase: PHASE2
-
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187 ·Status: COMPLETED
-
Health Related Quality of Life of Youth and Young Adults With Hemophilia A
NCT01034904 ·Status: COMPLETED
-
Long-term Anticoagulation in a Patient With Severe Hemophilia A
NCT07314983 ·Status: RECRUITING
-
Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
NCT02911233 ·Status: COMPLETED
-
Platelet Function in Patients With Hemophilia A
NCT02093065 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
NCT03191799 ·Status: COMPLETED ·Phase: PHASE3
-
International Immune Tolerance Study
NCT00212472 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
NCT04158648 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
NCT05248594 ·Status: COMPLETED
-
ATHN 7: Hemophilia Natural History Study
NCT03619863 ·Status: COMPLETED
-
Cooperative Study of Factor VIII Inhibitors
NCT00000582 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019 ·Status: RECRUITING